自身抗体血液检测联合影像学早期诊断肺癌的随机试验
2 年时干预组 III/IV 期肺癌诊断比例为 58.9%(33/56),对照组为 73.2%(52/71),风险比 0.64(95% CI 0.41-0.99),但肺癌死亡率和全因死亡率差异无统计学意义。
要点
- 干预组 III/IV 期肺癌诊断比例低于对照组(58.9% vs 73.2%),HR 0.64(95% CI 0.41-0.99)。
- 2 年时肺癌死亡率和全因死亡率差异无统计学意义。
- 该试验未设计评估 EarlyCDT-Lung 检测相对于低剂量 CT 的增量贡献。
核心结论
- 与标准临床诊疗相比,EarlyCDT-Lung 检测联合 CT 筛查使肺癌诊断出现向早期分期的转移。
- 肺癌死亡率和全因死亡率在 2 年时未观察到显著差异。
- 该分期转移的观察值得进一步研究,以评估 EarlyCDT-Lung 检测是否在低剂量 CT 标准之上有额外价值。
研究设计与样本
- 干预组接受 EarlyCDT-Lung 检测,检测阳性者每 6 个月接受低剂量 CT 扫描,持续至多 2 年。
- EarlyCDT-Lung 检测阴性者和对照组接受标准临床诊疗。
- 结局在随机化后 2 年评估,使用癌症发生、癌症分期、死亡率和合并症的有效数据。
主要发现
- 2 年时研究人群中共检出 127 例肺癌(1.0%)。
- 干预组 56 例肺癌中 33 例(58.9%)诊断为 III/IV 期,对照组 71 例中 52 例(73.2%)诊断为 III/IV 期。
- III/IV 期表现的风险比为 0.64(95% CI 0.41-0.99)。
- 2 年后肺癌死亡率和全因死亡率差异无统计学意义。
临床怎么用
- 对于肺癌风险人群,可考虑 EarlyCDT-Lung 检测联合低剂量 CT 筛查以促进早期诊断。
- 该策略对死亡率的获益尚未证实,需结合个体风险与后续研究评估。
局限性
- ECLS 比较的是 EarlyCDT-Lung 联合 CT 筛查与标准临床诊疗,未设计评估 EarlyCDT-Lung 检测的增量贡献。
- 2 年时肺癌死亡率和全因死亡率差异无统计学意义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The EarlyCDT-Lung test is a high-specificity blood-based autoantibody biomarker that could contribute to predicting lung cancer risk. We report on the results of a phase IV biomarker evaluation of whether using the EarlyCDT-Lung test and any subsequent computed tomography (CT) scanning to identify those at high risk of lung cancer reduces the incidence of patients with stage III/IV/unspecified lung cancer at diagnosis compared with the standard clinical practice at the time the study began.The Early Diagnosis of Lung Cancer Scotland (ECLS) trial was a randomised controlled trial of 12 208 participants at risk of developing lung cancer in Scotland in the UK. The intervention arm received the EarlyCDT-Lung test and, if test-positive, low-dose CT scanning 6-monthly for up to 2 years. EarlyCDT-Lung test-negative and control arm participants received standard clinical care. Outcomes were assessed at 2 years post-randomisation using validated data on cancer occurrence, cancer staging, mortality and comorbidities.At 2 years, 127 lung cancers were detected in the study population (1.0%). In the intervention arm, 33 out of 56 (58.9%) lung cancers were diagnosed at stage III/IV compared with 52 out of 71 (73.2%) in the control arm. The hazard ratio for stage III/IV presentation was 0.64 (95% CI 0.41-0.99). There were nonsignificant differences in lung cancer and all-cause mortality after 2 years.ECLS compared EarlyCDT-Lung plus CT screening to standard clinical care (symptomatic presentation) and was not designed to assess the incremental contribution of the EarlyCDT-Lung test. The observation of a stage shift towards earlier-stage lung cancer diagnosis merits further investigations to evaluate whether the EarlyCDT-Lung test adds anything to the emerging standard of low-dose CT.
引用
- Sullivan FM, Mair FS, Anderson W, et al. Earlier diagnosis of lung cancer in a randomised trial of an autoantibody blood test followed by imaging. Eur Respir J. 2021. PMID: 32732334. doi:10.1183/13993003.00670-2020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。